Trial Profile

A Phase 1 First-in-Human Study to Investigate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamic Activity of CLN-617 Alone and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 05 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs CLN 617 (Primary) ; Pembrolizumab (Primary)
Indications Head and neck cancer; Malignant melanoma; Solid tumours; Squamous cell cancer
Focus Adverse reactions; First in man; Therapeutic Use
Sponsors Cullinan Therapeutics

16 Apr 2024 According to Cullinan Therapeutics media release, Cullinan Oncology has changed its name to Cullinan Therapeutics.
14 Dec 2023 According to a Cullinan Oncology media release, the first patient has been dosed with CLN-617 in this trial.
06 Oct 2023 Planned initiation date (estimated date of first participant enrollment) changed from 1 Sep 2023 to 1 Oct 2023.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com